The VLVbio K18 assays in Clinical Trials
Investigation of Drug Candidates in Clinical Trials using the VLVbio K18 assays
In clinical trials, candidate drugs are administered to patients to investigate whether the drug induces cell death in tumours with sufficient efficacy. During this stage of anticancer drug development the M30 Apoptosense® ELISA and the M65® ELISA can be used to follow the time course and efficacy of the administred drugs and to investigate the cell death mechanism, i.e. whether the tumour cells die due to apoptosis or necrosis.